OakChart

Pacific Biosciences of California Inc

PACBHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 11:44 AM ET

2.18-0.06 (-2.58%)
2026-11-11 17:45 CET
Market cap
700.96 USD m
Revenue, TTM
161.39 USD m
Net income, TTM
-131.23 USD m
Free cash flow, TTM
-143.40 USD m
EPS diluted, TTM
-0.43
P/E
-
Compare

Price

PACB against its 20, 50 and 200-day averages
2050200beatearnings
1.002.003.0040.2M80.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PACBclose 2.1820-day 2.2850-day 1.98200-day 1.612.1852w high52w low

36.5% under the 52-week high of 3.44 on 6 Oct 2026. 52-week low 1.07 on 12 Aug 2026. Last 15 sessions, 55.6% high to low

Profile

PACB
52-week range, 47% of the way up
1.073.43

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

IndexRUT
Employees485
IPOOct 27, 2010
Beta2.22
ATR, 14d0.29
Rel volume1.19
Short float18.76%
Insider own8.56%
Inst own66.47%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap682.90M
Enterprise Value1.19B
Income-131.23M
Sales161.39M
Book/sh-0.20
Cash/sh0.64
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees485
IPOOct 27, 2010

Ratios

P/E-
Forward P/E-
PEG-
P/S4.23
P/B-
P/C3.42
P/FCF-
EV/EBITDA-
EV/Sales7.37
Quick Ratio3.72
Current Ratio4.62
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.43
EPS next Y-0.44
EPS next Q-0.13
EPS this Y76.01%
EPS next Y-1.15%
EPS next 5Y41.95%
EPS past 3/5Y-9.18% -
Sales past 3/5Y7.64% 15.19%
EPS Y/Y TTM74.75%
Sales Y/Y TTM4.41%
EPS Q/Q3.72%
Sales Q/Q5.52%
EarningsNov 04 AMC
EPS/Sales Surpr.10.78% 3.19%

Ownership

Insider Own8.56%
Insider Trans-2.51%
Inst Own66.47%
Inst Trans1.06%
ROA-17.22%
ROE-929.32%
ROIC-20.44%
Gross Margin32.52%
Oper. Margin-98.09%
Profit Margin-81.31%
SMA20-4.36%
SMA5010.19%
SMA20035.91%
Trades-

Technical

Shs Outstand312.24M
Shs Float286.13M
Short Float18.76%
Short Ratio4.33
Short Interest53.68M
52W High3.43 -36.47%
52W Low1.07 103.95%
Volatility13.20% 12.24%
ATR (14)0.29
RSI (14)48.27
Beta2.22
Rel Volume1.19
Avg Volume12.38M
Volume5,542,117

Performance

Perf Week-14.42%
Perf Month6.45%
Perf Quarter89.77%
Perf Half Y71.83%
Perf YTD16.70%
Perf Year17.33%
Perf 3Y-66.53%
Perf 5Y-91.91%
Perf 10Y-72.58%
Recom2.25
Target Price2.74
Prev Close2.24
Price2.18
Change %-2.58%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 09, 2026ResumedUUBSNeutral$1.35-38.1%
Mar 06, 2026DowngradeBBarclaysEqual Weight → Underweight$1.50-31.3%
Nov 11, 2024DowngradeUUBSBuy → Neutral
Jun 03, 2024ResumedJJefferiesBuy$4+83.3%
Apr 22, 2024DowngradeJJP MorganOverweight → Neutral
Apr 18, 2024DowngradeGGoldmanBuy → Neutral$7 → $2.50+14.6%
Dec 14, 2023InitiatedSStephensOverweight$11+404.1%
Dec 14, 2023InitiatedGGuggenheimNeutral
Dec 13, 2023InitiatedWWolfe ResearchPeer Perform
Nov 17, 2023UpgradeUUBSNeutral → Buy$13 → $10+358.2%

Peers

Mkt cap
TickerCompanyMkt cap
ILMNIllumina Inc32.97B
QSIQuantum-Si Incorporated293.36M
TXG10x Genomics Inc8.53B
LABStandard BioTools Inc273.44M
TMOThermo Fisher Scientific Inc268.50B
BRKRBruker Corp9.61B
BNGOBionano Genomics Inc16.00M
QGENQiagen NV10.41B
TWSTTwist Bioscience Corp9.06B
SEERSeer Inc88.60M

Insider trading

latest 14 of 20
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gibson James R IISee RemarksOct 06 '26Option Exercise1.18500,000590,0001,745,663Oct 08 04:07 PM
Gibson James R IISee RemarksOct 06 '26Sale3.11661,8152,056,9211,083,848Oct 08 04:07 PM
Jim GibsonOfficerOct 06 '26Proposed Sale2.87661,8151,899,409Oct 06 04:23 PM
Van Oene MarkSee RemarksAug 17 '26Sale1.1326,91130,4092,705,853Aug 18 08:17 PM
MARK VAN OENEOfficerAug 17 '26Proposed Sale1.1326,91130,512Aug 17 04:08 PM
Gibson James R IISee RemarksApr 01 '26Sale1.3788,185120,8131,245,663Apr 03 04:05 PM
JAMES GIBSONOfficerApr 01 '26Proposed Sale1.3788,185120,778Apr 01 05:17 PM
HENRY CHRISTIAN OSee RemarksMar 03 '26Sale1.5112,49718,9203,581,813Mar 04 05:55 PM
Van Oene MarkSee RemarksMar 03 '26Sale1.516,5049,8472,243,634Mar 04 05:54 PM
Farmer MicheleSee RemarksMar 03 '26Sale1.512,9794,510305,948Mar 04 05:54 PM
MARK D. VAN OENEOfficerMar 03 '26Proposed Sale1.516,5049,849Mar 03 04:24 PM
CHRISTIAN HENRYOfficerMar 03 '26Proposed Sale1.5112,49718,924Mar 03 04:20 PM
Van Oene MarkSee RemarksFeb 17 '26Sale1.58129,790204,5491,797,745Feb 19 08:33 PM
Van Oene MarkSee RemarksFeb 18 '26Sale1.6355,10789,7691,742,638Feb 19 08:33 PM

Held by

AUM
TickerCompanyAUM
ARKEARK DIET Q3 Buffer ETFAUM: 1.45M
ARKKARK Innovation ETFAUM: 5.97B
ARKGARK Genomic Revolution ETFAUM: 1.97B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 206
  • PacBio Beats On Sequential Rebound And Deep Cost Cuts, But Another Guidance Trim And Margin Squeeze Keep The Inflection Story Unproven (Earnings Whispers)
  • Pacific Biosciences: Q3 Earnings Snapshot (Associated Press)
  • PacBio Announces Third Quarter 2026 Financial Results (GlobeNewswire)
  • Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks But Pares Stake In This Pharma Giant That Had A Blowout Q3 (Stocktwits)
  • PacBio's SPARCnext Transition Faces Its First Real Test After Three Straight Guidance Cuts (Earnings Whispers) +8.89% +15.51%
  • Loading…
  • PacBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI (GlobeNewswire) +6.36%
  • PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
  • PacBio Sinks 8% as TychoBio Endorses Its Highest Quality Biological Data the Real Story Is More Complicated (TIKR) -5.92%
  • PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics (GlobeNewswire)
  • 3 Biotech Stocks Put Traders Are Targeting Today (Schaeffer's Research) +5.91%
  • PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference (GlobeNewswire)
  • Pacific Biosciences: Q2 Earnings Snapshot (Associated Press) -9.72% -10.38%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.120-0.135-0.12040.5639.317
2026Q22026-08-05-0.140-0.140-0.14439.0139.935
2026Q12026-05-07-0.030-0.142-0.02737.1839.946
2025Q42026-02-12-0.130-0.144-0.13444.6543.047
2025Q32025-11-05-0.130-0.151-0.12638.4440.107
2025Q22025-08-07-0.140-0.173-0.14039.7736.628
2025Q12025-05-08-1.440-0.192-1.43537.1535.4413
2024Q42025-02-130.010-0.190-0.47539.2240.1013
2024Q32024-11-07-0.220-0.221-0.22339.9741.9513
2024Q22024-08-07-0.640-0.233-0.63636.0140.8813
2024Q12024-05-09-0.290-0.276-0.29038.8143.4413
2023Q42024-02-15-0.310-0.287-0.30758.3657.4714
2023Q32023-10-30-0.260-0.289-0.26255.6948.7610
2023Q22023-08-02-0.280-0.320-0.27947.5740.1811
2023Q12023-05-02-0.360-0.332-0.36438.9034.388
2022Q42023-02-16-0.370-0.360-0.37327.3526.208

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.550-0.717-0.55290.8988.48
2020FY0.1700.1730.16878.8976.42
2021FY-0.890-0.854-0.888130.51130.49
2022FY-1.400-1.385-1.400128.3127.45
2023FY-1.210-1.177-1.209200.52199.19
2024FY-1.120-1.354-1.588154.01154.98
2025FY-1.820-1.848-1.820160.01158.43
2026FY--0.442--157.46
2027FY--0.432--178.46
2028FY--0.346--208.3
2029FY--0.235--238.9
2030FY--0.190--273.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0970441.1539.6042.97
2026Q4S2026-11-0670341.7939.6044.90
2026Q4S2026-11-0570242.2139.6044.90
2026Q4S2026-11-0470043.2139.8044.90
2026Q4S2026-10-2870043.2139.8044.90
2026Q4S2026-10-2070143.2139.8044.90
2026Q4S2026-10-1670643.2139.8044.90
2026Q4S2026-10-0670643.2239.8044.90
2026Q4S2026-09-0870643.2439.8044.90
2026Q4S2026-08-1460643.0739.8044.90
2026Q4S2026-08-0660543.4639.8045.37
2026Q4S2026-07-2660146.6545.0049.90
2026Q4S2026-07-2260246.6545.0049.90
2026Q4S2026-07-2161546.6545.0049.90

Estimate history

EPS, annual-0.87-0.759-0.5520.168-0.888-1.4-1.209-1.588-1.822-0.4264
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.223-0.475-1.435-0.14-0.126-0.134-0.027-0.144-0.122
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual93.46878.62690.89178.893130.513128.304200.521154.014160.005161.39
Period201720182019202020212022202320242025TTM
Sales, quarterly39.96739.22437.15339.76638.44144.64537.17839.00740.564
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual116.277150.244153.119192.294220.978226.505267.744294.418301.956312.237
Period201720182019202020212022202320242025MRQ
Shares, quarterly273.812294.418300.041300.35301.853301.956310.487310.81312.237
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue161.39160.00154.01200.52128.30130.5178.8990.8978.63
Cost of Goods Sold Incl. D&A108.91478.77130.34160.1879.4571.7346.3356.3153.53
Gross Profit52.48-318.7623.6840.3448.8558.7832.5734.5825.10
Selling, General and Administrative Excl. Other210.80232.94289.12350.71353.67236.95136.95135.12126.08
Research and Development85.1395.21129.02187.17193.00112.9064.1559.6362.59
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-158.31-551.70-265.44-310.37-304.82-178.16-104.39-100.55-100.99
Interest Expense7.656.9513.4114.3414.6912.530.272.612.42
Unusual Expense18.652.1654.4726.142.3832.27-98.000.020.17
Net Income Before Taxes-130.52-546.06-309.54-318.16-314.25-274.8729.40-84.13-102.56
Income Taxes0.710.320.32-11.420.00-93.650.000.000.00
Consolidated Net Income-131.23-546.38-309.85-306.74-314.25-181.2229.40-84.13-102.56
Net Income From Continuing Operations-131.23-546.38-309.85-306.74-314.25-181.2229.40-84.13-102.56
Net Income-131.23-546.38-309.85-306.74-314.25-181.2229.40-84.13-102.56
EPS (Recurring)-0.38-1.82-1.46-1.14-1.39-0.78-0.22-0.55-0.76
EPS (Basic, Before Extraordinaries)-0.43-1.82-1.13-1.21-1.40-0.890.18-0.55-0.76
EPS (Diluted)-0.43-1.82-1.59-1.21-1.40-0.890.17-0.55-0.76
EBITDA-141.36-165.30-212.10-277.67-287.50-166.58-95.08-90.60-93.77
Non-Operating Income (Expense)54.0914.7623.7832.687.64-51.9136.0519.041.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense25.1632.9256.1256.9778.6158.9317.5316.4023.15
Price To Earnings Ratio------309.18--
Price To Sales Ratio4.573.513.4312.4114.3232.0057.538.6312.71
Gross Margin32.52-199.2215.3720.1238.0845.0441.2838.0431.92
Operating Margin-98.09-344.80-172.35-154.78-237.58-136.51-132.31-110.62-128.44
Net Margin-81.31-341.47-201.18-152.97-244.92-138.8537.27-92.57-130.44
Shares Outstanding312.24301.96294.42267.74226.50220.98192.29153.12150.24
Market Capitalization700.96700.96501.172,623.631,849.574,513.444,856.56786.591,107.20

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue40.5639.0137.1844.6538.4439.7737.1539.22
Cost of Goods Sold Incl. D&A27.6327.2025.1728.9123.3721.52400.5733.80
Gross Profit12.9411.8012.0115.7315.0718.25-363.415.43
Selling, General and Administrative Excl. Other48.1456.4149.7656.4853.8841.2463.5768.61
Research and Development19.6223.0219.6122.8826.6518.7326.9527.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-35.20-44.61-37.75-40.75-38.81-22.99-426.99-63.19
Interest Expense2.062.111.741.741.741.741.742.76
Unusual Expense1.800.0016.400.450.0721.861.95-65.76
Net Income Before Taxes-37.58-44.68-8.09-40.17-37.62-41.90-426.383.89
Income Taxes0.270.060.180.200.380.04-0.300.32
Consolidated Net Income-37.85-44.74-8.28-40.37-38.00-41.93-426.073.57
Net Income From Continuing Operations-37.85-44.74-8.28-40.37-38.00-41.93-426.073.57
Net Income-37.85-44.74-8.28-40.37-38.00-41.93-426.073.57
EPS (Recurring)-0.12-0.140.01-0.13-0.13-0.09-1.43-0.62
EPS (Basic, Before Extraordinaries)-0.12-0.14-0.03-0.13-0.13-0.14-1.440.01
EPS (Diluted)-0.12-0.14-0.03-0.13-0.13-0.14-1.44-0.47
EBITDA-30.96-40.61-33.69-36.10-34.41-18.41-54.21-52.24
Non-Operating Income (Expense)1.482.0447.802.773.004.704.294.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.757.323.527.578.689.407.2712.67
Price To Sales Ratio4.573.282.523.532.492.382.303.65
Gross Margin31.8930.2632.3035.2439.2045.90-978.1513.84
Operating Margin-86.78-114.36-101.55-91.28-100.96-57.81-1,149.26-161.09
Net Margin-93.30-114.70-22.26-90.43-98.85-105.44-1,146.819.10
Shares Outstanding312.24310.81310.49301.96301.85300.35300.04294.42
Market Capitalization700.96521.81398.64564.57384.47372.11351.47501.17

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments279.53390.62631.72772.621,044.90319.6549.10102.3562.87
Short Term Receivables35.4527.5236.6218.7924.2416.8415.278.6013.43
Inventories49.2858.7656.6850.3824.6014.2313.3117.8823.07
Other Current Assets10.7918.7817.0410.296.694.872.772.832.25
Total Current Assets375.05495.68742.05852.071,100.43355.5980.45131.66101.62
Net Property, Plant & Equipment65.8446.6069.0381.3479.1254.8562.9034.0737.92
Total Investments and Advances1.531.532.422.924.593.504.004.504.50
Intangible Assets332.88707.33919.25820.22820.95---0.00
Other Assets8.779.3013.2710.531.870.040.640.040.04
Total Assets784.081,260.451,746.011,767.092,006.97413.98147.99170.28144.08
Short Term Debt Incl. Current Port. of LT Debt0.4512.2310.0810.739.314.3319.710.000.00
Accounts Payable20.7716.5915.0612.0311.003.588.376.749.09
Other Current Liabilities51.6137.4869.89240.5851.4030.5921.0820.1519.54
Total Current Liabilities72.8366.3095.03263.3371.7138.5049.1526.8828.64
Long Term Debt701.97662.41923.85938.25948.3437.6741.9614.6613.63
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities3.9325.1525.832.59195.942.321.9514.6715.71
Total Liabilities778.73753.851,044.711,204.181,215.9878.4993.0756.2157.98
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.35506.59701.30562.90790.99335.4954.92114.0686.10
Total Shareholders Equity5.35506.59701.30562.90790.99335.4954.92114.0686.10
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.35506.59701.30562.90790.99335.4954.92114.0686.10
Total Liabilities & Stockholders Equity784.081,260.451,746.011,767.092,006.97413.98147.99170.28144.08
Book Value Per Share0.021.722.622.493.581.740.360.760.74
Tangible Book Value Per Share-1.08-0.68-0.81-1.14-0.141.740.360.760.74
Full-Time Employees485575796769728412404401456
Price to Book Ratio-11.391.113.322.955.7214.8714.339.753.03
Return on Assets-53.45-20.61-17.46-16.65-14.9710.46-52.87-65.25-65.39
Return on Equity-213.45-51.30-48.53-46.42-32.1815.06-99.58-102.48-107.97
Return on Invested Capital-77.25-26.51-18.87-20.93-10.427.88-86.84-79.68-92.43
Quick Ratio4.476.597.213.0415.008.871.374.232.74
Current Ratio5.157.487.813.2415.359.241.644.903.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-131.23-546.38-309.85-306.74-314.25-181.2229.40-84.13-102.56
Depreciation16.97386.4153.3526.5317.3211.599.309.957.21
Other Funds (Non Cash)-15.4144.8691.2284.0387.69131.10-16.45-1.1223.25
Funds from Operations-129.67-115.65-165.48-207.59-209.24-132.1922.26-75.31-72.09
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-7.284.44-40.58-58.96-53.9721.00-2.76-3.005.67
Cash from Operating Activities-136.95-111.21-206.06-266.55-263.21-111.1819.50-78.31-66.43
Capital Expenditures-13.50-7.71-6.19-8.84-16.93-5.93-1.04-2.84-1.85
Net Assets From Acquisitions0.000.000.00-0.100.00-319.790.000.00-
Sale of Fixed Assets and Businesses50.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments98.47123.16130.1913.55133.01-352.81-218.2864.88-36.56
Purchase of Investments-94.26-216.91-498.63-756.57-442.79-988.05-373.28-57.73-122.18
Sale Or Maturity of Investments192.73340.07628.83770.12575.80635.24155.00122.6185.62
Other Uses-1.900.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities133.07115.45124.004.60116.08-678.53-219.3262.05-38.41
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock3.153.437.70204.5211.23326.65233.848.55107.18
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock3.153.437.70204.5211.23326.65233.848.55107.18
Proceedsfrom Stock Options0.000.000.00189.200.00294.85187.480.0097.53
Issuance or Reduction of Debt, Net0.000.00-50.69-1.84-1.61895.17-16.000.000.00
Change in Long Term Debt0.000.000.000.000.00895.540.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00895.540.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-86.410.00-52.2434.0018.000.00
Other Financing Activities Uses0.000.000.00-86.410.00-52.24-0.000.00
Cash from Financing Activities3.153.43-42.99116.279.621,169.58251.8426.55107.18
Net Change in Cash-0.737.67-125.04-145.68-137.51379.8752.0210.282.34
Free Cash Flow-143.40-113.92-212.25-275.39-279.96-117.1118.46-81.15-68.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow------245.81--
Deferred Taxes & Investment Tax Credit--0.55-0.20-11.420.00-93.650.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments199.45236.91275.98279.53298.95315.04
Short Term Receivables38.3231.1029.3535.4530.6232.26
Inventories60.2861.0851.0249.2853.1553.84
Other Current Assets9.809.5413.1610.7911.5112.27
Total Current Assets307.85338.64369.52375.05394.24413.40
Net Property, Plant & Equipment68.6967.3065.2265.8464.7166.61
Total Investments and Advances1.631.571.571.531.531.53
Intangible Assets329.93330.85331.87332.88333.90334.92
Other Assets13.0013.4914.198.778.789.01
Total Assets721.10751.85782.37784.08803.16825.47
Short Term Debt Incl. Current Port. of LT Debt2.071.370.280.450.620.70
Accounts Payable10.9219.2213.6120.7716.3615.05
Other Current Liabilities53.6148.2151.4751.6146.2344.00
Total Current Liabilities66.5968.8165.3672.8363.2159.75
Long Term Debt703.30704.76703.11701.97699.46698.52
Provision for Risks Charges8.350.000.000.000.000.00
Other Liabilities4.2311.5011.533.934.405.71
Total Liabilities782.48785.06780.00778.73767.07763.98
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-61.38-33.212.375.3536.0961.49
Total Shareholders Equity-61.38-33.212.375.3536.0961.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-61.38-33.212.375.3536.0961.49
Total Liabilities & Stockholders Equity721.10751.85782.37784.08803.16825.47
Book Value Per Share-0.20-0.110.010.020.120.20
Tangible Book Value Per Share-1.25-1.17-1.06-1.08-0.99-0.91
Full-Time Employees---485--
Price to Book Ratio-11.39220.4774.5315.646.254.06
Return on Assets-17.22-16.66-15.65-53.45-44.60-44.98
Return on Equity--929.32-273.55-213.45-205.41-189.52
Return on Invested Capital-5.90-6.66-1.17-5.71-5.17-5.52
Quick Ratio3.724.034.874.475.406.02
Current Ratio4.624.925.655.156.246.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-37.85-44.74-8.28-40.37-38.00-41.93
Depreciation4.254.004.074.654.404.58
Other Funds (Non Cash)7.9411.15-43.669.1611.6811.84
Funds from Operations-25.66-29.59-47.86-26.56-21.91-25.51
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-11.95-5.993.177.493.21-3.87
Cash from Operating Activities-37.60-35.58-44.69-19.07-18.71-29.38
Capital Expenditures-0.99-3.61-8.04-0.860.09-0.55
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.0050.000.000.000.00
Purchase or Sale of Investments32.1043.68-4.2026.8918.8225.83
Purchase of Investments-3.62-5.10-52.45-33.09-65.83-56.17
Sale Or Maturity of Investments35.7248.7848.2559.9884.6482.00
Other Uses0.000.00-1.900.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities31.1140.0735.8626.0318.9025.28
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.460.261.440.001.470.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.460.261.440.001.470.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.460.261.440.001.470.00
Net Change in Cash-5.044.74-7.396.961.66-4.09
Free Cash Flow-38.59-37.14-47.73-19.93-18.62-29.93

Revenue breakdown

Consumable2024: 70.37M 2025: 81.94M
Instrument2024: 65.78M 2025: 53.82M
Service And Other2024: 17.87M 2025: 24.25M
Americas2024: 78.71M 2025: 72.80M
Asia Pacific2024: 40.71M 2025: 43.16M
EMEA2024: 34.59M 2025: 44.05M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.76%53.7M286.1M11.88M
2026-10-1516.51%46.9M284.2M10.85M
2026-09-3016.56%47.2M285.1M8.02M
2026-09-1517.15%48.9M285.1M6.50M
2026-08-3117.39%49.6M285.1M6.69M
2026-08-1418.73%53.4M285.1M6.48M
2026-07-3117.08%49.0M286.9M6.21M
2026-07-1516.13%46.2M286.7M6.21M
2026-06-3016.57%47.5M286.7M6.40M
2026-06-1521.13%60.6M286.7M6.03M
2026-05-2917.03%48.7M286.0M6.10M
2026-05-1519.52%59.9M307.0M6.11M
2026-04-3017.25%47.1M273.0M6.23M
2026-04-1517.09%46.4M271.3M6.51M
2026-03-3116.82%45.6M271.3M7.05M
2026-03-1315.26%41.4M271.3M7.20M
2026-02-2714.08%38.2M271.3M7.17M
2026-02-1314.35%38.9M271.2M7.97M
2026-01-3013.14%35.6M270.8M8.55M
2026-01-1512.96%35.1M270.8M8.89M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.302.301.800.00035.000.000.958-0.0210.000
call1.000.851.801.4513.93017.000.000.897-0.0230.001
call1.500.601.351.089.2804790.000.816-0.0210.001
call2.000.250.400.252.3063,6084.000.665-0.0150.001
call2.500.000.200.102.2991,0709.000.423-0.0170.001
call3.000.000.050.031.81614,6300.000.170-0.0090.001
call3.500.000.450.102.3761,6070.000.141-0.0100.001
call4.000.000.100.102.8081,4550.000.125-0.0110.001
call4.500.000.750.053.1541.000.000.115-0.0120.001
call5.000.000.250.053.5111230.000.108-0.0120.001
call5.500.000.400.003.7550.000.000.102-0.0130.001
call6.000.001.000.003.9970.000.000.098-0.0130.001
put0.500.000.750.0012.3560.000.00-0.041-0.0210.000
put1.000.001.000.046.8351.000.00-0.103-0.0230.001
put1.500.001.000.124.1327.000.00-0.184-0.0210.001
put2.000.000.200.102.1614,4920.00-0.335-0.0150.001
put2.500.350.500.402.1701,8791.00-0.577-0.0170.001
put3.000.750.900.842.1832524.00-0.831-0.0080.001
put3.500.851.601.004.3881.000.00-0.860-0.0100.001
put4.001.651.901.933.2372.000.00-0.875-0.0110.001
put4.501.852.600.005.4690.000.00-0.885-0.0110.001
put5.002.203.200.006.6710.000.00-0.892-0.0120.001
put5.502.703.700.006.9660.000.00-0.898-0.0120.001
put6.003.204.200.007.3090.000.00-0.902-0.0120.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-10424B5SEC
2026-11-09SCHEDULE 13GSEC
2026-11-06SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-03SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-07-30SEC
2026-07-098-KCurrent report2026-07-08SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-05-27SDSpecialized Disclosure ReportSEC
2026-05-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10002.06M1
2026-090000
2026-080030.41K1
2026-070000
2026-060000
2026-050000
2026-0400120.81K1
2026-030033.28K3
2026-02001.13M6
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.10.41%
ARK Investment Management LLC9.59%
SOFTBANK GROUP CORP.6.58%
VANGUARD CAPITAL MANAGEMENT LLC4.31%
GEODE CAPITAL MANAGEMENT, LLC2.13%
Amova Asset Management Americas, Inc.1.93%
STATE STREET CORP1.92%
Sumitomo Mitsui Trust Group, Inc.1.59%
Point72 Asset Management, L.P.1.54%
TWO SIGMA INVESTMENTS, LP1.37%

Funds

Fund% owned
ARK Innovation ETF4.12%
ARK Genomic Revolution ETF3.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.07%
iShares Russell 2000 ETF2.37%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Fidelity Small Cap Index Fund0.98%
BlackRock Advantage Small Cap Core Fund0.83%
iShares Russell 2000 Growth ETF0.80%
iShares Biotechnology ETF0.64%
ARK Venture Fund0.56%

OakChart. PACB. Cached 15 minutes.